Maheshwari Anshul, the Chief Operating and Financial Officer of SI-BONE, Inc., has reported several stock sales to cover tax withholding obligations related to the vesting of restricted stock units. This move is significant as it showcases the company's approach to managing financial responsibilities while adhering to regulatory requirements.
SI-BONE, Inc., identified by its Central Index Key (CIK) 0001459839, operates in the surgical and medical instruments sector. The company is based in Santa Clara, California, and is incorporated in Delaware. The recent filings indicate that SI-BONE is actively engaged in the market, with Anshul playing a key role in its financial operations.
According to the recent SEC filing (accession number 0001853089-26-000009), Anshul executed multiple transactions on October 2 and October 5, 2026. In these transactions, he sold a total of 3,289 shares of common stock at prices ranging from approximately $18.17 to $19.50 per share. The filing specifies that these sales were necessary to meet tax obligations arising from the vesting of restricted stock units. Notably, the filing states, "The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units." This indicates a structured approach to managing equity compensation.
The implications of these transactions extend to both the company and its stakeholders. As the Chief Operating and Financial Officer, Anshul's actions reflect a commitment to transparency and compliance with SEC regulations. The sales do not indicate a shift in his overall ownership strategy, as he still retains a significant number of shares following these transactions. Post-sale, he holds 218,235 shares, including 160,823 shares that are issuable upon the settlement of restricted stock units.
Looking ahead, the filing does not specify any further actions or upcoming filings related to these transactions. However, the ongoing management of stock options and restricted units is likely to remain a critical focus for SI-BONE as it continues to navigate the competitive landscape of the surgical and medical instruments industry.